KFM 19

Drug Profile

KFM 19

Latest Information Update: 14 Jun 2001

Price : $50

At a glance

  • Originator Boehringer Ingelheim
  • Developer Boehringer Ingelheim; Pharmacia Corporation
  • Class Antidementias; Antidepressants; Neuroprotectants; Small molecules
  • Mechanism of Action Adenosine A1 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.


Highest Development Phases

  • No development reported Alzheimer's disease; Major depressive disorder

Most Recent Events

  • 14 Jun 2001 No-Development-Reported for Depression in Germany (Unknown route)
  • 14 Jun 2001 No-Development-Reported for Alzheimer's disease in USA (Unknown route)
  • 14 Jun 2001 No-Development-Reported for Alzheimer's disease in Germany (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top